



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/009,876	05/06/2002	Richard Gerardus F. Visser	92750/65	5153
759	90 12/10/2004	•	EXAM	INER
Amster Rothstein & Ebenstein			KALLIS, RUSSELL	
90 Park Avenue New York, NY 10016			ART UNIT	PAPER NUMBER
			1638	

DATE MAILED: 12/10/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/009,876	VISSER ET AL.				
Office Action Summary	Examiner	Art Unit				
•	Russell Kallis	1638				
The MAILING DATE of this communication app	The state of the s					
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on <u>06 May 2002</u> .						
2a) This action is FINAL . 2b) This	This action is FINAL . 2b)⊠ This action is non-final.					
3) Since this application is in condition for allowa	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 39-58 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 39-58 are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) M Notice of References Cited (RTO 903)						
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 	4) ☐ Interview Summary (Paper No(s)/Mail Da					
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application (PTO-152) 6) Other:						

Application/Control Number: 10/009,876

Art Unit: 1638

DETAILED ACTION

The election mailed 11/23/2004, which inadvertently did not include claims 51-58, is hereby VACATED and replaced with the instant restriction.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 39-50, 54-58 drawn to genetic construct suitable for transforming a plant comprising a polynucleotide encoding a starch binding domain and a GBSS1 from potato and transformed plants and seeds or tubers.

Group II, claim(s) 39-50, 54-58 drawn to a genetic construct suitable for transforming a plant comprising a polynucleotide encoding a starch binding domain and an *E. coli* glycogen branching enzyme and transformed plants and seeds or tubers.

Group III, claim(s) 39-50, 54-58 drawn to a genetic construct suitable for transforming a plant comprising a polynucleotide encoding a starch binding domain and a potato kinase R1 and transformed plants and seeds or tubers.

Group IV, claim(s) 51-53, drawn to a fusion protein.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of a nucleotide sequence that interacts with starch or starch granules was taught in the art. Chen *et al.*Biotechnology Progress, 1991, Vol. 7, pp. 225-229; teach improved adsorption to starch of a beta-galactosidase fusion protein containing the starch-binding domain from *Aspergillus* glucoamylase (see abstract). Further, the enzymes of Claim 40, (starch synthase I of Group I, glycogen branching enzyme of Group II, potato kinase R1 of Group III), are recognized in the art to each have a different core structure, different specific activities and would not be expected to behave in the same fashion, producing different products and phenotypes when transformed into a plant; and since separate consideration would be required for each enzyme, restriction into separate groups is proper (See MPEP, Annex B, Unity of invention, part I, (f)Markush practice).

Art Unit: 1638

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1638

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Russell Kallis whose telephone number is (571) 272-0798. The examiner can normally be reached on M-F 8:30-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (571) 272-0804. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Russell Kallis Ph.D. November 30, 2004